Investing.com – Evogene (NASDAQ: EVGN) reported third quarter EPS of $-1.310, $0.30 worse than the analyst estimate of $-1.010. Revenue for the quarter came in at $1.8M versus the consensus estimate of $2.85M.
Evogene's stock price closed at $1.65. It is down -57.470% in the last 3 months and down -72.650% in the last 12 months.
Evogene saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Evogene's stock price’s past reactions to earnings here.
According to InvestingPro, Evogene's Financial Health score is "fair performance".
Check out Evogene's recent earnings performance, and Evogene's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Comments (0)